218 related articles for article (PubMed ID: 36700734)
1. Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
Desch M; Schlecker C; Hohl K; Liesenfeld KH; Chan T; Müller F; Wunderlich G; Keller S; Ishiguro N; Wind S
J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):113-121. PubMed ID: 36700734
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
Ou YC; Tang Z; Novotny W; Tawashi M; Li TK; Coleman HA; Sahasranaman S
Br J Clin Pharmacol; 2021 Jul; 87(7):2926-2936. PubMed ID: 33336408
[TBL] [Abstract][Full Text] [Related]
3. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Kim MG; Kim Y; Jeon JY; Kim DS
Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
Zahir H; Kobayashi F; Zamora C; Gajee R; Gordon MS; Babiker HM; Wang Q; Greenberg J; Wagner AJ
J Clin Pharmacol; 2021 Mar; 61(3):298-306. PubMed ID: 32918831
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
6. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Tachibana M; Papadopoulos KP; Strickler JH; Puzanov I; Gajee R; Wang Y; Zahir H
Br J Clin Pharmacol; 2018 Jan; 84(1):112-121. PubMed ID: 28865153
[TBL] [Abstract][Full Text] [Related]
8. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
9. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
Greene SA; Kwak C; Kamin M; Vernillet L; Glenn KJ; Gabriel L; Kim HW
Clin Transl Sci; 2022 Apr; 15(4):899-911. PubMed ID: 34877801
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
11. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
Berger B; Kaufmann P; Berse M; Treiber A; Grignaschi N; Dingemanse J
Pharmacol Res Perspect; 2023 Oct; 11(5):e01143. PubMed ID: 37800597
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Snyder BD; Rowland A; Polasek TM; Miners JO; Doogue MP
Eur J Clin Pharmacol; 2014 Sep; 70(9):1115-22. PubMed ID: 25028073
[TBL] [Abstract][Full Text] [Related]
14. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Edwards JE; Eliot L; Parkinson A; Karan S; MacConell L
Adv Ther; 2017 Sep; 34(9):2120-2138. PubMed ID: 28808886
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Johansson S; Read J; Oliver S; Steinberg M; Li Y; Lisbon E; Mathews D; Leese PT; Martin P
Clin Pharmacokinet; 2014 Sep; 53(9):837-47. PubMed ID: 25117183
[TBL] [Abstract][Full Text] [Related]
18. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Khatri A; Cheng L; Camez A; Ignatenko S; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Jun; 58(6):805-814. PubMed ID: 30574672
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.
Nakamura T; Shimizu H; Kawaguchi A
Clin Ther; 2020 Nov; 42(11):2171-2183.e4. PubMed ID: 33153727
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Xiao JJ; Nowak D; Ramlau R; Tomaszewska-Kiecana M; Wysocki PJ; Isaacson J; Beltman J; Nash E; Kaczanowski R; Arold G; Watkins S
Clin Transl Sci; 2019 Jan; 12(1):58-65. PubMed ID: 30427584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
